Travere Therapeutics, INC Form 4 insider transactions

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, made a charitable gift of 891 shares of common stock under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised stock options and subsequently sold 10,000 shares under a pre-arranged 10b5-1 plan.

Travere Therapeutics CFO Christopher R. Cline reported the sale of 573 common shares in two transactions to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

Travere Therapeutics CFO Christopher R. Cline sold 470 shares of common stock for $17.31 per share, as part of a pre-arranged 10b5-1 plan to cover tax obligations.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold 815 shares of common stock at $14.65 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Director Brinkley Ruth Williams reports acquisition of 6,500 shares and disposal of 25,750 shares of Travere Therapeutics common stock on May 15, 2025, along with stock option grants.

Director Ron Squarer reports acquisition of 6,500 shares of common stock and 19,500 stock options, along with the disposal of 6,500 shares.

Director Sandra Poole reports acquiring shares and disposing of shares of Travere Therapeutics, Inc. common stock on May 15, 2025.

Director John A. Orwin acquired 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 15, 2025, according to a Form 4 filing.

Jeffrey A. Meckler, a director at Travere Therapeutics, received an automatic equity grant and disposed of shares on May 15, 2025.

Gary A. Lyons, a director of Travere Therapeutics, reports acquiring and disposing of common stock and stock options on May 15, 2025, according to a Form 4 filing.

Director Timothy Coughlin reports acquisition of 6,500 shares and disposal of shares of Travere Therapeutics, Inc. on May 15, 2025.

Director Suzanne Bruhn acquired 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics on May 15, 2025, under the company's equity incentive plan.

Roy D. Baynes, a director of Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 15, 2025, according to a Form 4 filing with the SEC.

Christopher R. Cline, CFO of Travere Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) and subsequent sale of shares to cover tax obligations.

Travere Therapeutics CEO Eric Dube exercised performance-based restricted stock units (PSUs) and sold a portion of the acquired shares to cover tax obligations.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, reports the vesting of performance-based restricted stock units and subsequent sale of shares to cover tax obligations.

William E. Rote, Chief Research Officer at Travere Therapeutics, reports the vesting of performance-based restricted stock units and subsequent sale of shares.

Elizabeth E. Reed, Chief Legal Officer and GC of Travere Therapeutics, exercised performance-based restricted stock units and sold shares to cover tax obligations following the achievement of a revenue-related performance criterion.

Christopher R. Cline, CFO of Travere Therapeutics, sold shares to cover tax withholding obligations related to vested restricted stock units.

William E. Rote, Senior Vice President of R&D at Travere Therapeutics, exercised performance-based restricted stock units (PSUs) and sold a portion of the acquired shares to cover tax obligations after the company confirmed a path forward for traditional approval of FILSPARI.

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, exercises performance-based restricted stock units (PSUs) and sells shares to cover tax obligations after a key regulatory milestone for FILSPARI.

Sandra Calvin, SVP and Chief Accounting Officer of Travere Therapeutics, exercised stock options and sold shares on February 11, 2025, according to a recent SEC Form 4 filing.

Chief Commercial Officer Peter Heerma exercised performance-based restricted stock units (PSUs) and sold shares of Travere Therapeutics following the confirmation of a path forward for traditional approval of FILSPARI in FSGS.

Travere Therapeutics CEO Eric Dube sold 11,375 shares of common stock at $24.04 per share on February 11, 2025, under a pre-arranged 10b5-1 trading plan.

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the satisfaction of clinical/regulatory performance criteria.

Director Roy D. Baynes exercised stock options and sold 10,000 shares of Travere Therapeutics (TVTX) common stock at $22 per share on February 6, 2025.

Senior Vice President of R&D at Travere Therapeutics, William E. Rote, reports acquisition and disposal of company stock and stock options.

Elizabeth Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, reports acquisition of restricted stock units and stock options, and the sale of common stock to cover tax obligations.

CEO Eric Dube reports acquisition and disposal of Travere Therapeutics stock, including sales to cover tax obligations.